Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

You are here:

Home
News
Business, Finances, Insurance & Regulatory
Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia

November 13, 2020

The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL.

This is great news for CLL patients in Europe. It is already approved in several countries including the USA.

For more details see the official press release.

About the author

Brad Hedrick

Chronic Lymphocytic Leukemia (CLL) Patients and Protection against COVID-19: Passive and Active Immunity, Monoclonal Antibodies and Vaccines
February 25, 2021

Trials Studying the Safety and Immune Response of Chronic Lymphocytic Leukemia (CLL) Patients Receiving the COVID-19 Vaccines
February 12, 2021

FDA approves lisocabtagene maraleucel (liso-cel or JCAR-017) a CAR-T cell therapy for relapsed or refractory large B-cell lymphoma
February 6, 2021

CLL Society Quoted by CNN: Are Covid-19 vaccines safe for cancer patients? Here is what cancer experts say by Lauren Kent, CNN
February 5, 2021

NCCN: Cancer and COVID-19 Vaccination
February 4, 2021

ERIC’s Official Statement: SARS-CoV-2 Vaccine in Patients with CLL
February 2, 2021